Adelphi Trust Co Invests $1.26 Million in Stryker Corporation $SYK

Key Points

• Adelphi Trust Co opened a new position in Stryker, purchasing 3,580 shares worth about $1.26 million, making SYK 1.0% of Adelphi's holdings and its 24th-largest holding.
• Stryker beat quarterly expectations, reporting $4.47 EPS vs. $4.40 expected and $7.17B in revenue (up 11.4% year-over-year), with analysts’ consensus rating a "Moderate Buy" and an average target near $421.
• Insider and institutional activity: Director Ronda E. Stryker sold 250,000 shares for roughly $90.7 million (a 9.23% drop in her stake), while institutional investors own about 77.09% of the stock and insiders own 4.60%.

Adelphi Trust Co acquired a new position in Stryker Corporation (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 3,580 shares of the medical technology company's stock, valued at approximately $1,258,000. Stryker makes up 1.0% of Adelphi Trust Co's holdings, making the stock its 24th largest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. LBP AM SA raised its stake in shares of Stryker by 3.3% in the 4th quarter. LBP AM SA now owns 240,681 shares of the medical technology company's stock worth $84,592,000 after buying an additional 7,639 shares in the last quarter. Consolidated Investment Group LLC grew its holdings in shares of Stryker by 24.7% in the 4th quarter. Consolidated Investment Group LLC now owns 13,110 shares of the medical technology company's stock worth $4,608,000 after acquiring an additional 2,600 shares during the last quarter. Valmark Advisers Inc. grew its holdings in shares of Stryker by 1.9% in the 4th quarter. Valmark Advisers Inc. now owns 2,363 shares of the medical technology company's stock worth $831,000 after acquiring an additional 43 shares during the last quarter. SeaBridge Investment Advisors LLC grew its holdings in shares of Stryker by 1.0% in the 4th quarter. SeaBridge Investment Advisors LLC now owns 7,888 shares of the medical technology company's stock worth $2,772,000 after acquiring an additional 78 shares during the last quarter. Finally, Sunpointe LLC grew its holdings in shares of Stryker by 19.7% in the 4th quarter. Sunpointe LLC now owns 972 shares of the medical technology company's stock worth $343,000 after acquiring an additional 160 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker agreed to acquire Amplitude Vascular Systems to add next‑generation IVL technology, expanding its peripheral vascular offerings and potentially accelerating addressable market growth in arterial disease — a strategic tuck‑in that investors generally view as growth‑accretive. Stryker to Acquire AVS (Zacks)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $397 price target, signaling continued analyst confidence in Stryker's growth and supporting upside expectations for the stock. BTIG Buy Reaffirmed
• Positive Sentiment: Leerink Partners initiated coverage on Stryker with an outperform/recommendation, adding another supportive institutional view that may help underpin the stock over time. Leerink Initiates Coverage (MSN)
• Neutral Sentiment: A separate initiation notice was posted by AmericanBankingNews; initiation increases institutional coverage and liquidity but its immediate directional impact depends on the report's stance and investor reaction. Leerink Initiates Coverage (AmericanBankingNews)
• Negative Sentiment: Truist lowered its price target from $395 to $380 and moved to a "hold" rating, reducing the implied upside and contributing to near‑term selling pressure as some investors mark positions to the lower PT. Truist Lowers Price Target (Benzinga)

Stryker Stock Performance

Shares of SYK stock opened at $341.74 on Thursday. Stryker Corporation has a 1-year low of $319.32 and a 1-year high of $404.87. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $130.88 billion, a price-to-earnings ratio of 40.68, a P/E/G ratio of 2.02 and a beta of 0.92. The stock's fifty day simple moving average is $353.78 and its 200-day simple moving average is $359.95.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the previous year, the company posted $4.01 earnings per share. Stryker's revenue for the quarter was up 11.4% compared to the same quarter last year. On average, sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business's stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. TD Cowen cut Stryker from a "buy" rating to a "hold" rating and set a $387.00 target price on the stock. in a report on Monday, January 26th. Barclays restated an "overweight" rating and issued a $469.00 target price on shares of Stryker in a report on Monday, February 2nd. Weiss Ratings restated a "hold (c+)" rating on shares of Stryker in a report on Monday, December 22nd. Needham & Company LLC lifted their target price on Stryker from $448.00 to $454.00 and gave the stock a "buy" rating in a report on Friday, January 30th. Finally, BTIG Research reiterated a "buy" rating and set a $397.00 price target on shares of Stryker in a report on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $421.11.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.